Early filing for melanoma drug adds to Merck's renewed R&D hopes
This article was originally published in Scrip
Executive Summary
After being criticized for much of the past year for having a stagnant research and development pipeline, investors on 13 January breathed new life into Merck's shares, which rose as high as 7.1% in morning trading, on the news the FDA had given the firm's experimental cardiovascular drug vorapaxar a positive review and the company had started the process of submitting a rolling biologics license application (BLA) for its investigational anti-PD-1 immunotherapy MK-3475, also known as lambrolizumab, in advanced melanoma.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.